Full Press Release Details
Medical Selected for Preliminary Inclusion to Russell Microcap Index
Mass., June 5, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular
Robotic System, announced that it has been selected for inclusion in the preliminary list
of additions to the Russell Microcap Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted
indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution
when the U.S. market opens on Monday, June 30, 2025.
annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30, 2025, ranking them by total
market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic
inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes.
indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Russell's US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are
part of FTSE Russell, the global index provider.
Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions
of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic
system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements
that contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, confirmation of inclusion in the final list of additions to the Russel Microcap
Index, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused
company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic
System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k)
clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty
resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the
FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and
the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing
Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports
filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law